Triglav Skladi D.O.O. Invests $1.44 Million in DexCom, Inc. (NASDAQ:DXCM)

Triglav Skladi D.O.O. acquired a new position in DexCom, Inc. (NASDAQ:DXCM - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 18,500 shares of the medical device company's stock, valued at approximately $1,439,000.

Other large investors have also recently bought and sold shares of the company. Private Trust Co. NA grew its holdings in DexCom by 266.3% in the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock valued at $26,000 after purchasing an additional 245 shares during the last quarter. Optiver Holding B.V. purchased a new position in DexCom during the fourth quarter worth about $33,000. TD Private Client Wealth LLC lifted its position in DexCom by 62.8% during the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock worth $34,000 after buying an additional 167 shares during the period. Larson Financial Group LLC lifted its position in DexCom by 40.5% during the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock worth $37,000 after buying an additional 137 shares during the period. Finally, Heck Capital Advisors LLC purchased a new position in DexCom during the fourth quarter worth about $38,000. Hedge funds and other institutional investors own 97.75% of the company's stock.

DexCom Stock Performance

Shares of DXCM traded down $0.06 during mid-day trading on Thursday, hitting $84.83. The stock had a trading volume of 1,693,852 shares, compared to its average volume of 4,361,280. The company has a market cap of $33.26 billion, a PE ratio of 59.32, a PEG ratio of 2.30 and a beta of 1.43. The company's fifty day simple moving average is $72.99 and its two-hundred day simple moving average is $77.92. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59. DexCom, Inc. has a fifty-two week low of $57.52 and a fifty-two week high of $129.97.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its earnings results on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing the consensus estimate of $0.33 by ($0.01). The firm had revenue of $1.04 billion during the quarter, compared to analyst estimates of $1.02 billion. DexCom had a return on equity of 30.14% and a net margin of 14.29%. DexCom's revenue was up 12.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.32 EPS. On average, equities analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current year.

Analyst Upgrades and Downgrades

DXCM has been the topic of a number of research reports. Barclays raised their price objective on DexCom from $90.00 to $93.00 and gave the stock an "equal weight" rating in a report on Monday, May 5th. Morgan Stanley raised their price objective on DexCom from $75.00 to $82.00 and gave the stock an "equal weight" rating in a report on Friday, February 14th. Redburn Atlantic upgraded DexCom from a "neutral" rating to a "buy" rating and raised their price objective for the stock from $85.00 to $115.00 in a report on Monday, February 3rd. Piper Sandler cut their price objective on DexCom from $100.00 to $90.00 and set an "overweight" rating on the stock in a report on Friday, May 2nd. Finally, Citigroup raised their target price on DexCom from $82.00 to $102.00 and gave the company a "buy" rating in a report on Thursday. Five analysts have rated the stock with a hold rating, thirteen have issued a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, DexCom currently has an average rating of "Moderate Buy" and a consensus target price of $98.00.

Insider Activity at DexCom

In other DexCom news, EVP Michael Jon Brown sold 13,000 shares of DexCom stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total transaction of $914,940.00. Following the sale, the executive vice president now owns 105,602 shares of the company's stock, valued at $7,432,268.76. The trade was a 10.96% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Jereme M. Sylvain sold 7,000 shares of DexCom stock in a transaction on Monday, March 10th. The shares were sold at an average price of $73.83, for a total value of $516,810.00. Following the sale, the executive vice president now directly owns 135,482 shares in the company, valued at $10,002,636.06. The trade was a 4.91% decrease in their position. The disclosure for this sale can be found here. Insiders sold 66,926 shares of company stock worth $4,734,384 in the last 90 days. 0.32% of the stock is currently owned by company insiders.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.